EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of Metformin in Preventing Herpes Zoster Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation

Shunsuke Hiroki, Toshiki Fukasawa iD, Kasumi Yokogawa, Koji Kawakami iD

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Shunsuke Hiroki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Herpes Zoster, Hypoglycemic Agents. Die Arbeit nennt 36 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with type 2 diabetes have a higher risk of herpes zoster (HZ). Although metformin may reduce this risk via immunomodulatory effects, prior evidence is limited by confounding by indication and an unclear causal estimand. We aimed to estimate the per‐protocol effect of sustained metformin use on the risk of HZ in comparison with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, for which no evidence suggests an elevated HZ risk. We emulated a target trial using a Japanese claims database (April 2012–December 2023) to assess the 4‐year risk of HZ among new users of either metformin or a DPP‐4 inhibitor. Risks were estimated using an inverse probability weighted pooled logistic regression model. Among 9691 metformin users, 154 developed HZ (weighted 4‐year risk: 4.18%), while among 17 202 DPP‐4 inhibitor users, 345 developed HZ (4.92%). The risk difference was −0.74% (95% CI, −1.80 to 0.39), and the risk ratio was 0.85 (95% CI, 0.66 to 1.08). In conclusion, metformin use did not reduce the 4‐year risk of HZ compared with DPP‐4 inhibitor use. This finding contradicts a prior observational report of a marked risk reduction, which was likely inflated by confounding by indication, and highlights the need to specify a clear causal estimand.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Herpes ZosterHypoglycemic AgentsHumansFemaleMaleAgedMiddle AgedJapanDipeptidyl-Peptidase IV InhibitorsAged, 80 and overAdultEast Asian People

Stichwörter der Autor:innen

herpes zostermetforminreal‐world datatarget trial emulationtype 2 diabetes

Substanzen

MetforminHypoglycemic AgentsDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
  • Research and Development, AstraZeneca K.K., Osaka, Japan.

ORCID-Profile: Toshiki Fukasawa, Koji Kawakami

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Hiroki, S., Fukasawa, T., Yokogawa, K., & Kawakami, K. (2025). Effectiveness of Metformin in Preventing Herpes Zoster Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation. Journal of Medical Virology. https://doi.org/10.1002/jmv.70606

Vancouver

Hiroki S, Fukasawa T, Yokogawa K, Kawakami K. Effectiveness of Metformin in Preventing Herpes Zoster Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation. Journal of Medical Virology. 2025. doi:10.1002/jmv.70606

BibTeX
@article{Hiroki2025,
  author = {Hiroki, Shunsuke and Fukasawa, Toshiki and Yokogawa, Kasumi and Kawakami, Koji},
  title = {Effectiveness of Metformin in Preventing Herpes Zoster Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70606}
}
Kostenlos starten →